Are you over 18 and want to see adult content?
More Annotations
A complete backup of arma3-servers.net
Are you over 18 and want to see adult content?
A complete backup of theengineblock.com
Are you over 18 and want to see adult content?
A complete backup of empregodf.com.br
Are you over 18 and want to see adult content?
A complete backup of frauenchorwochenende.de
Are you over 18 and want to see adult content?
A complete backup of waterbugtours.com
Are you over 18 and want to see adult content?
A complete backup of angelomeola.co.uk
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of accessonline.com
Are you over 18 and want to see adult content?
A complete backup of kettleandfire.com
Are you over 18 and want to see adult content?
A complete backup of dcpracticeinsights.com
Are you over 18 and want to see adult content?
A complete backup of nutrizionepiu.it
Are you over 18 and want to see adult content?
Text
STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. EVERSENSE CGM SYSTEM SENSEONICS CONFIDENTIAL l NOVEMBER 2020 The world’s first and only long-term CGM Tim Goodnow, PhD President and CEO EVERSENSE ® CGM SYSTEM Credit Suisse 29th Annual Virtual Healthcare ConferenceNovember 15, 2020
SENSEONICS ADDED TO THE RUSSELL 2000® INDEX GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the company has been added to the Russell 2000 ® Index following the reconstitution of Russell ACCURACY AND LONGEVITY OF AN IMPLANTABLE CONTINUOUS Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A Prospective Multi-center Pivotal TrialINTRODUCTION
SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. EVERSENSE CGM SYSTEM SENSEONICS CONFIDENTIAL l NOVEMBER 2020 The world’s first and only long-term CGM Tim Goodnow, PhD President and CEO EVERSENSE ® CGM SYSTEM Credit Suisse 29th Annual Virtual Healthcare ConferenceNovember 15, 2020
SENSEONICS ADDED TO THE RUSSELL 2000® INDEX GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the company has been added to the Russell 2000 ® Index following the reconstitution of Russell ACCURACY AND LONGEVITY OF AN IMPLANTABLE CONTINUOUS Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A Prospective Multi-center Pivotal TrialINTRODUCTION
STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS ANNOUNCES INITIATION OF EUROPEAN COMMERCIAL GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL Fourth Quarter 2020 Results: Total revenue for the quarter was $3.9 million compared to $9.0 million for the fourth quarter of 2019. U.S. revenue was $0.4 million and revenue outside the U.S. was $3.5 million . Fourth quarter 2020 gross profit increased by $10.8 million year-over-year, to $2.6 million. The positive gross margin in thequarter
SENSEONICS ANNOUNCES A POSITIVE COVERAGE DECISION FOR EmblemHealth coverage decision adds nearly 2.9 million covered lives for Eversense CGMGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for SENSEONICS HOLDINGS INCREASES PREVIOUSLY ANNOUNCED BOUGHT GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) (“Senseonics” or the “Company”), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that, due to demand, the underwriter has agreed to increase the sizeEXECUTIVE TEAM
President & CEO. Tim Goodnow is the President and Chief Executive Officer at Senseonics, Inc. Tim joined the Senseonics Board of Directors in December 2010 and in March 2011 was named President & CEO. Tim has been instrumental in commercializing the first 90-day Eversense CGM System in Europe and the 180-day product - Eversense XL- which is
PRODUCT ALERTS
3/5/2020 Background On March 3, 2020, the U.S. Food and Drug Administration announced the potential threat of a set of cybersecurity vulnerabilities, referred to as SweynTooth, that were publicly disclosed in mid-February by security researchers at Singapore University of Technology and Design. These potential CAREERS – SENSEONICS Careers. Senseonics is committed to a working environment where individuals can thrive in a creative, challenging and professional environment. At the heart of what we do is our dedication to our customers – people with diabetes, their families and their caregivers – who trust our products to become integral parts oftheir lives.
SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS HOLDINGS, INC. REPORTS THIRD QUARTER 2020 Third quarter 2020 general and administrative expenses increased by $0.1 million year-over-year, to $5.5 million. The increase was primarily due to an increase in stock-based compensation expenses. Net loss was $23.4 million, or $0.10 per share, in the third quarter of 2020, compared to $19.5 million, or $0.10 per share, in the thirdquarter of
CAREERS – SENSEONICS Careers. Senseonics is committed to a working environment where individuals can thrive in a creative, challenging and professional environment. At the heart of what we do is our dedication to our customers – people with diabetes, their families and their caregivers – who trust our products to become integral parts oftheir lives.
SENSEONICS ADDED TO THE RUSSELL 2000® INDEX GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the company has been added to the Russell 2000 ® Index following the reconstitution of Russell SENSEONICS ANNOUNCES PARTNERSHIP WITH COMPANION MEDICAL February 11, 2020. Senseonics Announces Partnership with Companion Medical. Eversense long-term CGM and InPen System to integrate sensor glucose and insulin data. GERMANTOWN, Md. -- (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the firstand
PRESENTATIONS & EVENTS Raymond James 39th Annual Institutional Investor Conference in Orlando, Florida on Wednesday, March 7, 2018 at 9:15am ET. 03/07/2018. Related Materials. Listen to webcast. LEERINK Partners 7th Annual Global Healthcare Conference. Senseonics’ management is scheduled to present Wednesday, February 14, 2018 at 1:00pm ET. 02/14/2018. SENSEONICS LAUNCHES THE EVERSENSE® BRIDGE PATIENT ACCESS Patients Can Access Long-term Eversense CGM for only $99 * Under Program. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of SENSEONICS ANNOUNCES EXTENSION OF DISTRIBUTION AGREEMENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue Results and Issues 2019 Financial GuidanceConference Call Monday, February 4, 2019 at 8:00 a.m. ETGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, ACCURACY AND LONGEVITY OF AN IMPLANTABLE CONTINUOUS Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial DOI: 10.2337/dc16-1525 SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS HOLDINGS, INC. REPORTS THIRD QUARTER 2020 Third quarter 2020 general and administrative expenses increased by $0.1 million year-over-year, to $5.5 million. The increase was primarily due to an increase in stock-based compensation expenses. Net loss was $23.4 million, or $0.10 per share, in the third quarter of 2020, compared to $19.5 million, or $0.10 per share, in the thirdquarter of
CAREERS – SENSEONICS Careers. Senseonics is committed to a working environment where individuals can thrive in a creative, challenging and professional environment. At the heart of what we do is our dedication to our customers – people with diabetes, their families and their caregivers – who trust our products to become integral parts oftheir lives.
SENSEONICS ANNOUNCES PARTNERSHIP WITH COMPANION MEDICAL Eversense long-term CGM and InPen System to integrate sensor glucose and insulin data. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system, today announced an agreement with BENEFITS – SENSEONICS Senseonics greatly values its employees as the most important asset in our success. Which is why we offer a set of benefits that we believe are among our industry's very best. By offering advantages that enhance the quality of your life, and that of your family, we SENSEONICS ADDED TO THE RUSSELL 2000® INDEX GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the company has been added to the Russell 2000 ® Index following the reconstitution of Russell PRESENTATIONS & EVENTS Raymond James 39th Annual Institutional Investor Conference in Orlando, Florida on Wednesday, March 7, 2018 at 9:15am ET. 03/07/2018. Related Materials. Listen to webcast. LEERINK Partners 7th Annual Global Healthcare Conference. Senseonics’ management is scheduled to present Wednesday, February 14, 2018 at 1:00pm ET. 02/14/2018. SENSEONICS ANNOUNCES EXTENSION OF DISTRIBUTION AGREEMENT GERMANTOWN, Md. -- (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with RocheDiabetes Care
SENSEONICS LAUNCHES THE EVERSENSE® BRIDGE PATIENT ACCESS Patients Can Access Long-term Eversense CGM for only $99 * Under Program. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES A POSITIVE COVERAGE DECISION FOR EmblemHealth coverage decision adds nearly 2.9 million covered lives for Eversense CGMGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS LAUNCHES EVERSENSE CGM SYSTEM WITH NON The Eversense ® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are stillrequired for
EVERSENSE CGM SYSTEM SENSEONICS CONFIDENTIAL l NOVEMBER 2020 The world’s first and only long-term CGM Tim Goodnow, PhD President and CEO EVERSENSE ® CGM SYSTEM Credit Suisse 29th Annual Virtual Healthcare ConferenceNovember 15, 2020
SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13,STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS ANNOUNCES A POSITIVE COVERAGE DECISION FOR EmblemHealth coverage decision adds nearly 2.9 million covered lives for Eversense CGMGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS LAUNCHES EVERSENSE CGM SYSTEM WITH NON The Eversense ® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are stillrequired for
EVERSENSE CGM SYSTEM SENSEONICS CONFIDENTIAL l NOVEMBER 2020 The world’s first and only long-term CGM Tim Goodnow, PhD President and CEO EVERSENSE ® CGM SYSTEM Credit Suisse 29th Annual Virtual Healthcare ConferenceNovember 15, 2020
SENSEONICS HOLDINGS, INC. REPORTS FIRST QUARTER 2021 First quarter 2021 general and administrative expenses decreased by $0.72 million year-over-year, to $4.97 million. The decrease was primarily due to a decrease in personnel related costs. Net loss was $249.51 million, or $0.68 per share, in the first quarter of 2021, compared to $42.59 million, or $0.21 per share, in the first quarterof 2020.
SENSEONICS HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year SENSEONICS ANNOUNCES A POSITIVE COVERAGE DECISION FOR EmblemHealth coverage decision adds nearly 2.9 million covered lives for Eversense CGMGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems forEXECUTIVE TEAM
President & CEO. Tim Goodnow is the President and Chief Executive Officer at Senseonics, Inc. Tim joined the Senseonics Board of Directors in December 2010 and in March 2011 was named President & CEO. Tim has been instrumental in commercializing the first 90-day Eversense CGM System in Europe and the 180-day product - Eversense XL- which is
SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL Fourth quarter 2019 total revenue, net grew 25% compared to the prior year period. Gross revenue for the fourth quarter of 2019 was $10.7 million, including U.S. gross revenue of $2.5 million . Fourth quarter 2019 gross profit decreased by $3.3 million year-over-year, to ($8.2) million. The decrease in gross profit was primarily due toPRODUCT ALERTS
3/5/2020 Background On March 3, 2020, the U.S. Food and Drug Administration announced the potential threat of a set of cybersecurity vulnerabilities, referred to as SweynTooth, that were publicly disclosed in mid-February by security researchers at Singapore University of Technology and Design. These potential SENSEONICS ANNOUNCES INITIATION OF EUROPEAN COMMERCIAL GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has PRESENTATIONS & EVENTS Raymond James 39th Annual Institutional Investor Conference in Orlando, Florida on Wednesday, March 7, 2018 at 9:15am ET. 03/07/2018. Related Materials. Listen to webcast. LEERINK Partners 7th Annual Global Healthcare Conference. Senseonics’ management is scheduled to present Wednesday, February 14, 2018 at 1:00pm ET. 02/14/2018. SENSEONICS ADDED TO THE RUSSELL 2000® INDEX GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the company has been added to the Russell 2000 ® Index following the reconstitution of Russell SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of theSTOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13, SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of theSTOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13, SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICS HOLDINGS, INC. REPORTS FIRST QUARTER 2021 First quarter 2021 general and administrative expenses decreased by $0.72 million year-over-year, to $4.97 million. The decrease was primarily due to a decrease in personnel related costs. Net loss was $249.51 million, or $0.68 per share, in the first quarter of 2021, compared to $42.59 million, or $0.21 per share, in the first quarterof 2020.
SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring CAREERS – SENSEONICS Careers. Senseonics is committed to a working environment where individuals can thrive in a creative, challenging and professional environment. At the heart of what we do is our dedication to our customers – people with diabetes, their families and their caregivers – who trust our products to become integral parts oftheir lives.
SENSEONICS ANNOUNCES A POSITIVE COVERAGE DECISION FOR EmblemHealth coverage decision adds nearly 2.9 million covered lives for Eversense CGMGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for BENEFITS – SENSEONICS Senseonics greatly values its employees as the most important asset in our success. Which is why we offer a set of benefits that we believe are among our industry's very best. By offering advantages that enhance the quality of your life, and that of your family, we SENSEONICS ANNOUNCES INITIATION OF EUROPEAN COMMERCIAL GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has SENSEONICS ANNOUNCES PARTNERSHIP WITH COMPANION MEDICAL Eversense long-term CGM and InPen System to integrate sensor glucose and insulin data. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system, today announced an agreement with PRESENTATIONS & EVENTS Raymond James 39th Annual Institutional Investor Conference in Orlando, Florida on Wednesday, March 7, 2018 at 9:15am ET. 03/07/2018. Related Materials. Listen to webcast. LEERINK Partners 7th Annual Global Healthcare Conference. Senseonics’ management is scheduled to present Wednesday, February 14, 2018 at 1:00pm ET. 02/14/2018. SENSEONICS LAUNCHES THE EVERSENSE® BRIDGE PATIENT ACCESS Patients Can Access Long-term Eversense CGM for only $99 * Under Program. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of SENSEONICS ANNOUNCES EXTENSION OF DISTRIBUTION AGREEMENT GERMANTOWN, Md. -- (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with RocheDiabetes Care
SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of theSTOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13, SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE Senseonics. Creators of the first and only. Long-term Implantable CGM. EXPLORE THE TECHNOLOGY. Senseonics. SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of theSTOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13, SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4 SENSEONICS ANNOUNCES THE FDA APPROVAL TO CONTINUE THE –The cohort of Eversense ® CGM users will also test modified sensor chemistry.–. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense ® CGM System – today announced the SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA August 10, 2020. Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care. Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring. Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity. SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategic SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, HOME USE ACCURACY OF THE EVERSENSE CGM SYSTEM WHEN … Background Methods Results Conclusions Eighteen people, 15 men, mean age 40 years and T1D duration 23 years were included (Table 1). In total, 15,826 data pairs were gener- SENSEONICS HOLDINGS, INC. REPORTS FIRST QUARTER 2021 First quarter 2021 general and administrative expenses decreased by $0.72 million year-over-year, to $4.97 million. The decrease was primarily due to a decrease in personnel related costs. Net loss was $249.51 million, or $0.68 per share, in the first quarter of 2021, compared to $42.59 million, or $0.21 per share, in the first quarterof 2020.
CAREERS – SENSEONICS Careers. Senseonics is committed to a working environment where individuals can thrive in a creative, challenging and professional environment. At the heart of what we do is our dedication to our customers – people with diabetes, their families and their caregivers – who trust our products to become integral parts oftheir lives.
BENEFITS – SENSEONICS Senseonics greatly values its employees as the most important asset in our success. Which is why we offer a set of benefits that we believe are among our industry's very best. By offering advantages that enhance the quality of your life, and that of your family, we SENSEONICS SUBMITS PMA APPLICATION FOR 180-DAY EVERSENSE PROMISE Study Demonstrated Strong Accuracy Performance, Consistent with Current Eversense CGM System GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring SENSEONICS HOLDINGS, INC. REPORTS THIRD QUARTER 2020 Third quarter 2020 general and administrative expenses increased by $0.1 million year-over-year, to $5.5 million. The increase was primarily due to an increase in stock-based compensation expenses. Net loss was $23.4 million, or $0.10 per share, in the third quarter of 2020, compared to $19.5 million, or $0.10 per share, in the thirdquarter of
SENSEONICS ANNOUNCES INITIATION OF EUROPEAN COMMERCIAL GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) hasBOARD OF DIRECTORS
Board of Directors. Stephen P. DeFalco. Mr. DeFalco was elected as a director and chairman in December 2015. Mr. DeFalco served as chairman of the Senseonics, Incorporated board of directors from June 2010 to December 2015 and served as Senseonics, Incorporated’s interim Chief Executive Officer from 2010 to March 2011. Mr. PRESENTATIONS & EVENTS Raymond James 39th Annual Institutional Investor Conference in Orlando, Florida on Wednesday, March 7, 2018 at 9:15am ET. 03/07/2018. Related Materials. Listen to webcast. LEERINK Partners 7th Annual Global Healthcare Conference. Senseonics’ management is scheduled to present Wednesday, February 14, 2018 at 1:00pm ET. 02/14/2018. SENSEONICS LAUNCHES THE EVERSENSE® BRIDGE PATIENT ACCESS Patients Can Access Long-term Eversense CGM for only $99 * Under Program. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of SENSEONICS ANNOUNCES EXTENSION OF DISTRIBUTION AGREEMENT GERMANTOWN, Md. -- (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with RocheDiabetes Care
SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE 2020 ATTD: Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor Over Multiple Sensor Insertionand Removal Cycles
STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the PROMISE Study SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4EXECUTIVE TEAM
President & CEO. Tim Goodnow is the President and Chief Executive Officer at Senseonics, Inc. Tim joined the Senseonics Board of Directors in December 2010 and BENEFITS – SENSEONICS Senseonics greatly values its employees as the most important asset in our success. Which is why we offer a set of benefits that we believe are among our industry's very best. By offering advantages that enhance the quality of your life, and that of your family, wePRODUCT ALERTS
3/5/2020 Background On March 3, 2020, the U.S. Food and Drug Administration announced the potential threat of a set of cybersecurity vulnerabilities, referred to as SweynTooth, that were publicly disclosed in mid-February by security researchers at Singapore University of Technology and Design. These potential PRESENTATIONS & EVENTS Senseonics Investor Call PARTICIPANT DIAL IN (TOLL FREE): 1-877-883-0383 PARTICIPANT INTERNATIONAL DIAL IN: 1-412-902-6506 Conference ID: 5389400 SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, ACCURACY AND LONGEVITY OF AN IMPLANTABLE CONTINUOUS Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial DOI: 10.2337/dc16-1525 SENSEONICSLEADERSHIPINVESTOR RELATIONSCAREERSSIGN UP FOR UPDATESPRESENTATIONS & EVENTSOUR PEOPLE 2020 ATTD: Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor Over Multiple Sensor Insertionand Removal Cycles
STOCK INFORMATION
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the PROMISE Study SENSEONICS HOLDINGS, INC. SCHEDULES FOURTH QUARTER AND GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, March 4EXECUTIVE TEAM
President & CEO. Tim Goodnow is the President and Chief Executive Officer at Senseonics, Inc. Tim joined the Senseonics Board of Directors in December 2010 and BENEFITS – SENSEONICS Senseonics greatly values its employees as the most important asset in our success. Which is why we offer a set of benefits that we believe are among our industry's very best. By offering advantages that enhance the quality of your life, and that of your family, wePRODUCT ALERTS
3/5/2020 Background On March 3, 2020, the U.S. Food and Drug Administration announced the potential threat of a set of cybersecurity vulnerabilities, referred to as SweynTooth, that were publicly disclosed in mid-February by security researchers at Singapore University of Technology and Design. These potential PRESENTATIONS & EVENTS Senseonics Investor Call PARTICIPANT DIAL IN (TOLL FREE): 1-877-883-0383 PARTICIPANT INTERNATIONAL DIAL IN: 1-412-902-6506 Conference ID: 5389400 SENSEONICS AND BETA BIONICS PARTNER ON DEVELOPMENT OF THE Long-term, implantable continuous glucose sensor to be integrated with bionic pancreas system GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, ACCURACY AND LONGEVITY OF AN IMPLANTABLE CONTINUOUS Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial DOI: 10.2337/dc16-1525 SENSEONICS ANNOUNCES RESULTS OF THE PROMISE STUDY -Overall MARD of 8.5%-9.1% during 180 Day Period. GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced the results of the PROMISE Study SENSEONICS HOLDINGS, INC. SCHEDULES FIRST QUARTER 2021 GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, May 13, SENSEONICS ANNOUNCES INITIATION OF EUROPEAN COMMERCIAL GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has SENSEONICS ANNOUNCES STRATEGIC COLLABORATION WITH ASCENSIA Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in Blood Glucose Monitoring Company has Entered into Financing Agreements for up to $80 Million to Provide Additional Liquidity Senseonics to Focus Streamlined Operations on Manufacturing, Research and Development of Next OUR PEOPLE – SENSEONICS Senseonics is committed to a working environment where individuals can thrive in a creative, challenging and professional environment. At the heart of what we do is our dedication to our customers – people with diabetes, their families and their caregivers – who trust ourproducts to
SENSEONICS ENTERS INTO NEW CREDIT FACILITIES WITH CERTAIN New credit facilities provide up to $20 million in near-term liquidityIn combination with cost-reduction initiatives, provide runway to complete value-enhancing development activities to seek approval of 180-day productSenseonics continues to pursue its previously announced exploration of strategicBOARD OF DIRECTORS
Mr. DeFalco was elected as a director and chairman in December 2015. Mr. DeFalco served as chairman of the Senseonics, Incorporated board of directors from June 2010 to December 2015 and served as Senseonics, Incorporated’s interim Chief Executive Officer from 2010 to March2011.
SENSEONICS ANNOUNCES A POSITIVE COVERAGE DECISION FOR --HCSC coverage decision adds more than 16 million covered lives for Eversense CGM--GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring CAREERS – SENSEONICS 06/03/2019. About the Position . The Regional Clinical Manager is a seasoned professional responsible for managing a team of exceptional clinical professionals charged with providing clinical, technical and product knowledge to healthcare providers with focus on the successful execution of 1) the Eversense procedures and 2) clinic onboardingprocess.
SEC FILINGS
20451 Seneca Meadows Parkway Germantown, MD 20876-7005. Main: (301) 515-7260 Fax: (301) 515-0988 skip to main content * __Sign Up for Updates* Products
* Products
* Product Alerts
* Leadership
* Executive Team
* Board Of Directors * Investor Relations* Stock Information
* Events & Publications* SEC Filings
* News Releases
* Corporate Governance* Email Alerts
* Careers
* Products
* Products
* Product Alerts
* Leadership
* Executive Team
* Board Of Directors * Investor Relations* Stock Information
* Events & Publications* SEC Filings
* News Releases
* Corporate Governance* Email Alerts
* Careers
* Products
* Leadership
* Investor Relations* Careers
SENSEONICS
Creators of the first and only Long-term Implantable CGM EXPLORE THE TECHNOLOGYSENSEONICS
News & Events
Publication
2020 ATTD: Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor Over Multiple Sensor Insertionand Removal Cycles
Publication
2020 ATTD: Percent of Patients with Targeted Time in Range and Time in Hypoglycemia with the Eversense CGM SystemPublication
2020 ATTD: Correlation Between Time in Range and Glucose Management Indicator with the Eversense CGM System* Products
* Products
* Product Alerts
* Leadership
* Executive Team
* Board Of Directors * Investor Relations* Stock Information
* Events & Publications* SEC Filings
* News Releases
* Corporate Governance* Email Alerts
* Careers
CONTACT US
20451 Seneca Meadows Parkway Germantown, MD 20876-7005 Main: (301) 515-7260Fax: (301) 515-0988
Senseonics © 2020.
Contact Us
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0